New valve offers hope for High-Risk heart patients
NCT ID NCT07334691
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new device called the Cardiovalve system to treat severe tricuspid regurgitation, a condition where a heart valve leaks. About 150 people aged 18-84 who are too high-risk for open-heart surgery will receive the valve. The goal is to see if the valve safely reduces leakage and improves daily function and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRICUSPID REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Uniklinik Bonn -
RECRUITINGBonn, 53127, Germany
Contact